AUTL (Autolus Therapeutics) Earnings per share growth rate in current year

Corporate emblem and logo of Autolus Corp (AUTL)

Autolus Therapeutics (AUTL) is minimizing regulatory risks by diversifying its CAR-T programs through a flexible platform. High demand from specialized clinics for leukemia treatments is driving business expansion. However, manufacturing complexities and competition create certain vulnerabilities. The annual percentage trend of earnings per share clearly demonstrates these processes, with the metric currently standing at 28.00.

AUTL: Autolus Therapeutics PLC Earnings per share growth in current year 07/04/2022 - 11/14/2026

Financial and market metric breakdowns for autolus.com (AUTL)

- price and consensus price forecast:
Stock Quotes Autolus Pharma|AUTL - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Autolus Therapeutics plc|AUTL - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Autolus Therapeutics|AUTL - Company Book Value|Market Value to Book Value Ratio autolus.com|AUTL - Cumulative Company Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Autolus Therapeutics|AUTL - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Autolus Therapeutics plc|AUTL - Company Aggregate Debts|Debts to Book Value Autolus Therapeutics plc|AUTL - Company Long-Term Debt|Company Short-Term Indebtedness Autolus Therapeutics|Immediate Liquidity autolus.com
- earnings and valuation multiples information:
AUTL - Net Income|Expected Net Income Autolus Therapeutics|AUTL - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Autolus Therapeutics|AUTL - PEG Multiple|Business Value to Operating Income Before Depreciation Autolus Therapeutics|AUTL - Operating profit EBITDA|Net earnings per one share for the last twelve months Autolus Therapeutics|AUTL - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months autolus.com|AUTL - Earnings growth in current year|Earnings growth forecast for next year Autolus Therapeutics
- revenue and sales proceeds data:
AUTL - Company Revenue|Company Expected Revenue Autolus Therapeutics|AUTL - Market Cap to Revenue|Market Cap to Future Revenue Ratio Autolus Therapeutics
Fundamental valuation:AUTL Autolus Corp
Manufactured products of Autolus Therapeutics

This metric serves as a critical filter during asset stress testing, allowing for an assessment of the real dynamics of shareholder value generation. It measures the annual rate of change in earnings per share, while the YoY earnings per share growth rate for Autolus Therapeutics (AUTL) reflects the efficiency of scaling cell therapies and the success in overcoming logistical barriers in biomaterial delivery.

Main competitors

Net earnings per share growth this year Legend Biotech Inc.|SANA (Sana Biotechnology Inc) - Earnings growth in current year|Earnings per share growth rate in current year allogene.com ALLO|Earnings per share growth in current year Cartesian Therapeutics, Inc. (RNAC)|Earnings per share growth in current year CLLS (Cellectis SA)|Earnings per share growth in current year Caribou Bio CRBU|Earnings per share increase in current year TIL|GNTA: Net earnings per share growth this year|Earnings per share increase in current year IPSC (centurytx.com)|JSPR: Earnings growth in current year|Net earnings per share change in current year Senti Bio SNTI|ADAP (Adaptimmune Therapeutics plc) - Earnings growth in current year|Earnings per share growth rate in current year cero.bio CERO|Earnings per share growth in current year Alaunos (TCRT)|Achilles Therapeutics plc - Earnings per share growth this year|Earnings growth in current year CRGX (CARGO Therapeutics, Inc)|Poseida (PSTX) - Earnings per share growth rate in current year|TSVT: Net earnings per share growth this year|Earnings per share increase in current year GRCL (Gracell Biotechnologies)